International Hepatology Archives - Page 45 of 47

AASLD Interview | Professor Wai-Kay Seto’s Team: Presentation of Five Achievements in Predicting Clinical Cure of Hepatitis B and Post-operative Recurrence of Liver Cancer, and Commentary on Liver Disease Research Trends

By Mourabit Halima 2023.12.20

The 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) has just concluded in Boston, USA. The team led by Professor Wai-Kay Seto from the University of Hong Kong focused on five research outcomes in the areas of mother-to-child transmission blockage and clinical cure of Hepatitis B, clearance of Hepatitis C, post-operative recurrence of liver cancer, and post-liver transplant management. These outcomes were presented at the meeting, with two of them being shared in the form of oral presentations. Professor Seto's team has been committed to the clinical management and scientific research of chronic liver diseases, achieving fruitful results. Hepatology Digest invited the team's principal researchers to interpret the findings and comment on the trends in liver disease research and share their experiences at the conference. The interview video is shared below.

Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

By Peter W. PENG 2023.12.20

The AASLD 2023 Annual Meeting, hosted by the American Association for the Study of Liver Diseases, recently concluded in Boston, USA. A team led by Professor Lili Liu and Associate Researcher Xuejing Zou from Southern Medical University's Nanfang Hospital in China, including Physician Ziyong Zhang, presented their research in the field of Metabolism-Associated Steatohepatitis (MASH) during the conference's oral presentations (Oral 38). Their study suggests that targeting macrophages may offer a new strategy to inhibit the progression of MASH to liver fibrosis. Dr. Ziyong Zhang was invited to introduce their research at the conference and share his experiences and insights.

AASLD Interview | Professor Bernd Schnabl: Delving into the “Gut-Liver Axis,” Decoding the Role of Gut Microbiota in the Diagnosis and Treatment of Autoimmune Liver Diseases

By Mourabit Halima 2023.12.14

The gut microbiome, a complex ecosystem within the human intestinal tract, has a broad impact on physiological functions. Gut microbiome imbalance has become one of the most critical environmental factors in the onset of chronic inflammatory diseases. The liver is one of the first identified targets of autoimmune attack. In recent years, with deeper research into the gut microbiome, the relationship between gut microbiota and liver diseases has gained increasing attention. Studies have found that gut microbiota might play a role in the development and progression of autoimmune liver diseases, making the treatment of gut microbiota imbalance a potential key target.

AASLD Interview丨Professor Jeffrey V. Lazarus: Clinical Management, Research Priorities, and Future Action Plans for MASLD

By Mourabit Halima 2023.12.14

The 2023 American Association for the Study of Liver Diseases (AASLD 2023) recently concluded in Boston, USA. metabolic dysfunction-associated steatotic liver disease (MASLD) was a key topic at the conference. In the "Healthy Liver, Healthy Lives" session, experts discussed how to reverse the global MASLD trend and what actions to take to address MASLD management challenges. Dr. Jeffrey V. Lazarus, head of the Health Systems Research Group at ISGlobal in Barcelona, Spain, attended the meeting and gave an interview to "Hepatology Digest" afterward. The interview video and the transcript in both English and Chinese are compiled below.

AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

By Peter W. PENG 2023.11.14

From November 10th to 14th, the annual international event in hepatology—the American Association for the Study of Liver Diseases (AASLD) 2023—was grandly held in Boston, USA. According to incomplete statistics, more than 200 abstracts from Chinese experts and scholars were selected for oral presentations or poster exchanges at this conference, achieving fruitful results. Congratulations are extended here! The Beijing University People's Hospital and Peking University Hepatology Institute team achieved 1 oral and 9 poster presentations on scientific research in the fields of hepatic encephalopathy, fatty liver, hepatitis C, hepatitis B, and liver cancer. Some research abstracts are shared below, and "Hepatology Digest" takes you to appreciate the team's excellence.

AASLD2023 | Unveiling the Four Prestigious “Distinguished Awards” on the First Day of the Conference!

By Peter W. PENG 2023.11.14

From November 10th to 14th, the grand finale of the international hepatology scene, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023, unfolded in Boston, USA. AASLD, in its annual tradition, awarded the "Distinguished Awards" during the conference to honor peers who have made significant strides in the field of hepatology. The recipients of the coveted 2023 "Distinguished Awards" were announced on the conference's inaugural day (local time, November 10th).

Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

By Peter W. PENG 2023.11.14

On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College of Medicine, who discussed his team's model predicting the changing prevalence of liver diseases in the U.S. until 2050. Dr. Zobair Younossi, the Global NASH Council Chairman, presented the latest findings on the correlation between food insecurity and MAFLD in American adolescents. Additionally, Dr. Rohit Loomba shared insights into the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD) and the challenges associated with it.

AASLD 2023: 17 Must-See Studies

By Peter W. PENG 2023.11.14

From November 10th to 14th, the annualHepatology Digest conference, the American Association for the Study of Liver Diseases (AASLD) 2023 held in Boston, USA. This event gathers the latest academic developments, clinical research findings, and major academic presentations in the field of liver disease. The following is a summary of 17 highly anticipated studies scheduled for presentation at the AASLD 2023 conference.

Doctor Philippa Easterbrook: WHO to Release New Hepatitis B Guidelines, Focusing on Expanding Treatment Eligibility and Simplifying Diagnosis and Treatment Pathways

By Xiaorong JI 2023.10.24

At the 58th European Association for the Study of the Liver (EASL) Annual Meeting (EASL 2023) and EASL Congress 2023, Doctor Philippa Easterbrook, Senior Scientist at the Global Hepatitis Programme of the Department of HIV at the World Health Organization (WHO) headquarters in Geneva, attended the WHO-ECDC Joint Forum. She discussed the new directions being drafted in WHO's updated Hepatitis B guidelines, focusing on expanding simplified treatment criteria, service delivery, and innovative diagnostics. Hepatology Digest had the privilege to interview Doctor Philippa Easterbrook about WHO's 2030 goals, the progress of the new Hepatitis B guidelines, essential information, and the global challenges and opportunities in addressing Hepatitis B prevention and control.

EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis B Research

By Xiaorong JI 2023.10.24

The 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023 have brought forth a splendid academic gathering for the global hepatology community. The Hepatology Digest reporting team had the privilege of interviewing Doctor Thomas Berg, EASL Secretary-General and Head of the Hepatology Department at Leipzig University Hospital. He shared with us the highlights of this conference, his perspective on significant research developments, thoughts on the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD), and insights into the future research directions for fatty liver and hepatitis B.